Return on Tangible Equity: The amount of net income returned as a percentage of shareholders equity, after subtracting intangible assets, goodwill and preferred equity. Calculated as: Income from Continuing Operations / Tangible Shareholders Equity
CytoMed Therapeutics Limited (GDTC) had Return on Tangible Equity of -28.17% for the most recently reported fiscal year, ending 2024-12-31.
| Income Statement Financials | |
$0.05M |
|
$-1.84M |
|
-- |
|
$0.05M |
|
$1.16M |
|
$-1.11M |
|
$-0.74M |
|
$-1.85M |
|
$-1.85M |
|
$-1.85M |
|
$-1.85M |
|
$-1.85M |
|
$-1.85M |
|
$-1.11M |
|
$-0.87M |
|
11.54M |
|
11.54M |
|
$-0.16 |
|
$-0.16 |
|
| Balance Sheet Financials | |
$4.39M |
|
$2.38M |
|
$2.98M |
|
$7.37M |
|
$0.44M |
|
$0.31M |
|
$0.31M |
|
$0.75M |
|
$6.62M |
|
$6.55M |
|
$6.62M |
|
11.54M |
|
| Cash Flow Statement Financials | |
$-1.98M |
|
$0.82M |
|
$-0.05M |
|
$4.56M |
|
$3.44M |
|
$-1.12M |
|
-- |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
9.89 |
|
-- |
|
-- |
|
0.04 |
|
0.05 |
|
100.00% |
|
-2183.07% |
|
-2183.07% |
|
-1700.54% |
|
-3628.51% |
|
-3621.08% |
|
$-3.01M |
|
-- |
|
-- |
|
-- |
|
0.01 |
|
-- |
|
0.07 |
|
5411.02 |
|
-27.89% |
|
|
Return on Tangible Equity |
-28.17% |
-25.05% |
|
-26.66% |
|
$0.57 |
|
$-0.26 |
|
$-0.17 |
|